Shree Ganesh Remedies Ltd Growth Catalysts - SOIC x StockScans Report

as of Nov 2026

  1. Revenue doubling guide - Management reaffirmed that revenue can double over the next 3 years from the FY27 exit run-rate, on existing products across agrochemicals, electronics and semiconductor applications for Southeast Asia and Europe, with project size and volumes intact. Against FY26 revenue of ₹92 cr, that implies roughly ₹180 cr+ of annual revenue by around FY30, driven by the CRAMS pipeline below.
  2. Japanese CRAMS launch - For the Southeast Asia specialty chemicals project with the Japanese partner, pilot trials are complete, batches are in stability testing, and commercial supplies are expected from Q1 FY28, with clarity on commercial volumes due by end of Q4 FY27. Management expects CRAMS projects to reach peak commercial quantities in 3 years, taking total Plant 7A utilisation to around 80%.
  3. Plant 7A commissioning - Construction of Plant 7A at Ankleshwar, built specifically for the CRAMS projects, is complete with water trials done and commercial production starting shortly. This removes the main capacity bottleneck ahead of the Q1 FY28 supply start, and a further commercial plant is already planned adjacent to it.
  4. European molecule wins - Two European molecules (pharma and agrochemical applications) are progressing, one approved-source agrochemical product carries commercial orders scheduled from Q4 FY27, and a second-source project has samples with the customer for stability studies with commercial orders expected in coming quarters. Project sizes have grown from 20-50 tonnes/year to 80-100 tonnes/year, with inquiries now above 500 tonnes/year.
  5. Domestic pharma intermediate launches - Commercial production of two new pharmaceutical intermediates (anti-diabetic and cardiovascular) began in Q2 FY27 with encouraging domestic response and export plans in coming quarters. These target products India imports from China where SGRL's existing chemistry earns decent margins, and management expects the core business to recover to earlier levels over the next few quarters.
  6. Block 8 ramp-up - Block 8, commissioned with ₹15 cr of capex completed in FY25, is targeting 50-60% utilisation by end of FY26. With the capital already spent, rising utilisation converts directly into revenue and margin, reversing the drag from higher depreciation and finance costs noted in FY25.